ReviewJournal of pharmaceutical analysis2025
Decoding protein dynamics with limited proteolysis coupled to mass spectrometry: A comprehensive review.
Review in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- DT-TRAP enables accurate target recognition via simplified dosing and low-temperature incubation.Journal of pharmaceutical analysis · 2026Article
- A historical journey of metabolite-protein interaction discovery: from data harmonization to AI-driven prediction.Briefings in bioinformatics · 2026Review
- Mass Spectrometry Proteomics: A Key to Faster Drug Discovery.Journal of medicinal chemistry · 2026Review
- Proteomics-Based Approaches to Decipher the Molecular Strategies ofJournal of fungi (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteins are indispensable to all biological systems and drive life processes through activities that are intricately linked to their three-dimensional (3D) structures. Traditional proteomics often provides static snapshots of protein expression, leaving unanswered questions about how proteins respond to stimuli and affect cellular functions. Limited proteolysis coupled with mass spectrometry (LiP-MS) has emerged as a powerful technique for exploring protein structure and function under near-natural conditions. Studies have revealed that LiP-MS is invaluable for structural and functional proteomics because it offers novel insights into protein dynamics. In this review, we summarise the current applications of LiP-MS in diverse areas such as the discovery and identification of drug targets, metabolite action mechanisms, proteome dynamics, protein interactions, and disease biomarkers. We also address the critical challenges in ongoing research and discuss their broader implications for advancing our understanding of protein biology and drug discovery. LiP-MS holds significant promise for accelerating biomarker and therapeutic target development as well as advancing molecular biology research in animals, plants, and microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.